Online Exclusives

Online Exclusives

Study of BI-505 for Multiple Myeloma Terminated

A phase II study of the investigational antibody BI-505 for patients with multiple myeloma (MM) was terminated after being put on a clinical hold...

CMS Proposes New Payment Program to Lower Medicare Drug Costs

The Centers for Medicare & Medicaid Services (CMS) announced an experimental initiative to test new ways to pay for certain prescription drugs, in an...

FDA Grants Pracinostat Breakthrough Designation for Older Patients With AML

The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for pracinostat in combination with azacitidine for patients with newly diagnosed acute myeloid...

CDC Reports That Brain Cancer Surpasses Leukemia as Leading Cause of Cancer Mortality in...

A report from the National Center for Health Statistics – part of the Centers for Disease Control and Prevention (CDC) – found that nearly...

World Health Organization Urges Necessity of the Affordable Care Act

The World Health Organization (WHO) urged U.S. President-elect Donald Trump to expand the Affordable Care Act once he is in office. Agnes Soucat, the director...

Socioeconomic Factors May Impact Multiple Myeloma Survival

A study found that two specific socioeconomic factors – household income and education level – play an important role in long-term survival among patients...

Clinical Trial of Investigational Multiple Myeloma Drug BI-505 Placed on Hold

A phase II study evaluating the investigational agent BI-505 for patients with multiple myeloma (MM) was placed on full clinical hold by the U.S....

Manufacturer of Blinatumomab Seeks Expanded U.S. FDA Approval for Pediatric ALL

A supplemental biologics license application has been submitted to the U.S. Food and Drug Administration (FDA) to expand blinatumomab’s approval to include the treatment...

Europe’s CHMP Recommends Ixazomib for Multiple Myeloma

Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended approval for ixazomib in combination with lenalidomide and dexamethasone for patients with multiple myeloma...

Conference Coverage: Updates on Idelalisib in CLL and FL: Superior PFS and Durable Responses

CHICAGO—Two posters presented at the 2015 ASCO Annual Meeting provided encouraging data for the use of the pi3k delta inhibitor idelalisib in the treatment...
Advertisement

Current Issue

April 2021 Volume 7 Issue 5

This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.

Block title